explore -WSS

explore

author：explore 2025-09-03 12:06:15 - browse：91

An artist's rendering of the building — currently under construction along Boston's Fort Point Channel — where Eli Lilly plans to open its Institute for Genetic Medicine. Courtesy Alexandria Real Estate Equities Inc

Eli Lilly and Co., which transformed itself from a stodgy underperformer into one of the world’s hottest pharmaceutical companies, said this week that the genetic medicine research center it plans to open in Boston in August will eventually employ twice as many workers as originally estimated.

In February 2022, Lilly said that it would increase its modest Massachusetts workforce from 120 to 250 employees when it opened the $700 million Lilly Institute for Genetic Medicine along Fort Point Channel. The Indianapolis-based company said it would move 120 scientists from Kendall Square in Cambridge to the institute and add another 130.

But Daniel Skovronsky, Lilly’s chief scientific and medical officer, said in an interview that the 12-story, 334,000-square-foot laboratory and office building will ultimately accommodate 500 Lilly scientists and researchers.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Ripples from Flovent's discontinuation is killing children with asthma

leisure time

WSS

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Boston hospital trains restaurant workers on naloxone for overdoses

Unique patient identifier: Experts argue the benefits, pitfalls

WuXi Biologics beefs up its lobbying operation

WuXi Biologics beefs up its lobbying operation

Adopting new red light myopia treatments may be short

leisure time

explore

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Affirmative action in medical school literally saved lives

Readout LOUD: Venture capital, Gilead, and more M&A

Hepatitis C has a cure — but many Americans still lack access to it

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Sports medicine is finally prioritizing gender equality

Readout Newsletter: Amgen, Regeneron, BGI Group and more

explore

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

HHS suspends federal funding for EcoHealth Alliance

Why Novartis is going to walk from its acquisition of MorphoSys

The White House hikes tariffs on plastic syringes made in China

Adopting new red light myopia treatments may be short

Updated Covid vaccine has 54% effectiveness, new study suggests

explore

leisure time

focus

hotspot